metronidazole has been researched along with Koch's Disease in 12 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the activity of metronidazole on persisting tubercle bacilli, BALB/c mice were infected with Mycobacterium tuberculosis and, after 14 days, treated with isoniazid (H) or rifampicin (R) or isoniazid + rifampicin (HR) for 2 months." | 7.70 | Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. ( Herbert, D; Kubendiran, G; Paramasivan, CN, 1998) |
| "The capacity of metronidazole to inhibit the growth of Mycobacterium tuberculosis was tested in in vitro and in vivo mouse models." | 7.70 | Metronidazole therapy in mice infected with tuberculosis. ( Brooks, JV; Furney, SK; Orme, IM, 1999) |
| "To study the activity of metronidazole on persisting tubercle bacilli, BALB/c mice were infected with Mycobacterium tuberculosis and, after 14 days, treated with isoniazid (H) or rifampicin (R) or isoniazid + rifampicin (HR) for 2 months." | 3.70 | Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. ( Herbert, D; Kubendiran, G; Paramasivan, CN, 1998) |
| "The capacity of metronidazole to inhibit the growth of Mycobacterium tuberculosis was tested in in vitro and in vivo mouse models." | 3.70 | Metronidazole therapy in mice infected with tuberculosis. ( Brooks, JV; Furney, SK; Orme, IM, 1999) |
| " difficile infection after TB medication was not low considering the relatively low TB medication dosage compared to other antibiotics." | 1.43 | Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication. ( Huh, KC; Jang, BI; Jung, Y; Kim, SH; Koo, HS; Lee, SW; Lee, YM; Moon, HS; Shin, JE; Yoon, SM, 2016) |
| "2h) and low absolute bioavailability (1." | 1.42 | Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ( Chaturvedi, V; Dasgupta, A; Gupta, AD; Jaiswal, S; Kashyap, VK; Khan, SR; Krishnan, MY; Lal, J; Roy, KK; Saxena, AK; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Srivastava, R, 2015) |
| "Non-pulmonary tuberculosis is found with different frequencies in different countries of the world." | 1.33 | Acute isolated tuberculous appendicitis. ( Głowacka, M; Kurek, J; Sandelewski, A; Wyrobiec, G, 2006) |
| "tuberculosis have reaffirmed tuberculosis as a primary public health threat." | 1.31 | A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. ( Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stover, CK | 1 |
| Warrener, P | 1 |
| VanDevanter, DR | 1 |
| Sherman, DR | 1 |
| Arain, TM | 1 |
| Langhorne, MH | 1 |
| Anderson, SW | 1 |
| Towell, JA | 1 |
| Yuan, Y | 1 |
| McMurray, DN | 1 |
| Kreiswirth, BN | 1 |
| Barry, CE | 1 |
| Baker, WR | 1 |
| Chopra, S | 1 |
| Koolpe, GA | 1 |
| Tambo-Ong, AA | 1 |
| Matsuyama, KN | 1 |
| Ryan, KJ | 1 |
| Tran, TB | 1 |
| Doppalapudi, RS | 1 |
| Riccio, ES | 1 |
| Iyer, LV | 1 |
| Green, CE | 1 |
| Wan, B | 1 |
| Franzblau, SG | 1 |
| Madrid, PB | 1 |
| Singh, S | 1 |
| Roy, KK | 1 |
| Khan, SR | 1 |
| Kashyap, VK | 1 |
| Sharma, A | 1 |
| Jaiswal, S | 1 |
| Sharma, SK | 1 |
| Krishnan, MY | 1 |
| Chaturvedi, V | 1 |
| Lal, J | 1 |
| Sinha, S | 1 |
| Dasgupta, A | 1 |
| Gupta, AD | 1 |
| Srivastava, R | 1 |
| Saxena, AK | 1 |
| Lee, YM | 1 |
| Huh, KC | 1 |
| Yoon, SM | 1 |
| Jang, BI | 1 |
| Shin, JE | 1 |
| Koo, HS | 1 |
| Jung, Y | 1 |
| Kim, SH | 1 |
| Moon, HS | 1 |
| Lee, SW | 1 |
| Wyrobiec, G | 1 |
| Sandelewski, A | 1 |
| Głowacka, M | 1 |
| Kurek, J | 1 |
| Paramasivan, CN | 1 |
| Kubendiran, G | 1 |
| Herbert, D | 1 |
| Brooks, JV | 1 |
| Furney, SK | 1 |
| Orme, IM | 1 |
| Dick, T | 2 |
| Sander, P | 1 |
| Papavinasasundaram, KG | 1 |
| Stavropoulos, E | 1 |
| Ellrott, K | 1 |
| Springer, B | 1 |
| Colston, MJ | 1 |
| Böttger, EC | 1 |
| Gray, JA | 1 |
| Geddes, AM | 1 |
| Woodruff, AW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Metronidazole Combined With Antituberculous Chemotherapy vs. Antituberculous Chemotherapy With Placebo in Subjects With Multi-Drug Resistant Pulmonary Tuberculosis[NCT00425113] | Phase 2 | 35 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00425113)
Timeframe: 2 months
| Intervention | days (Median) |
|---|---|
| Metronidazole | 21 |
| Placebo | 42.5 |
Lesions were defined as nodules (<2 mm, 2-<4 mm, and 4-10 mm), consolidations, collapse, cavities, fibrosis, bronchial thickening, tree-in-bud opacities, and ground glass opacities. Each CT was divided into six zones (upper, middle, and lower zones of the right and left lungs) and independently scored for the above lesions by three separate radiologists blinded to treatment arm. A fourth radiologist adjudicated any scores that were widely discrepant among the initial three radiologists. The HRCT score was determined by visually estimating the extent of the above lesions in each lung zone as follows: 0=0% involvement; 1= 1-25% involvement; 2=26-50% involvement; 3=51-75% involvement; and 4=76-100% involvement. A composite score for each lesion was calculated by adding the score for each specific abnormality in the 6 lung zones and dividing by 6, with the change in composite score measured at 2 and 6 months compared to baseline. Composite sums of all 10 composite scores are reported. (NCT00425113)
Timeframe: 6 months.
| Intervention | reader score (Mean) | |
|---|---|---|
| Baseline composite sum of all 10 features | Month 6 composite sum of all 10 features | |
| Metronidazole | 8.11 | 6.64 |
| Placebo | 10.08 | 7.24 |
1 review available for metronidazole and Koch's Disease
| Article | Year |
|---|---|
Antibacterial prophylaxis--a clinician's view.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Child; Child, Preschool; Female; Hum | 1979 |
11 other studies available for metronidazole and Koch's Disease
| Article | Year |
|---|---|
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Mul | 2000 |
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Discovery; Female; Isomerism; Mice; Mice, | 2012 |
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Topics: Adenosine Triphosphate; Animals; Antitubercular Agents; Male; Mice; Mice, Inbred BALB C; Molecular D | 2015 |
Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotics, Antitubercular; Clostridioides d | 2016 |
Acute isolated tuberculous appendicitis.
Topics: Adult; Amikacin; Antibiotics, Antitubercular; Antitubercular Agents; Appendicitis; Appendix; Female; | 2006 |
Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Metronidazole; Mice; M | 1998 |
Metronidazole therapy in mice infected with tuberculosis.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Macrophages; Metronidazole; Mice; Mycoba | 1999 |
Dormant tubercle bacilli: the key to more effective TB chemotherapy?
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Humans; Interphase; Metronidazole; Mice; Myc | 2001 |
Mycobacterium bovis BCG recA deletion mutant shows increased susceptibility to DNA-damaging agents but wild-type survival in a mouse infection model.
Topics: Alkylating Agents; Animals; Anti-Bacterial Agents; Blotting, Western; DNA Damage; DNA Repair; Drug R | 2001 |
Imported infections. Unexplained fever.
Topics: Africa; Asia; Brucellosis; Chloramphenicol; Chloroquine; Fever; Humans; Leishmaniasis, Visceral; Liv | 1974 |
Current practice in tropical medicine.
Topics: Acute Kidney Injury; Amebiasis; Amebicides; Chloroquine; Cholera; Drug Resistance, Microbial; Hepati | 1969 |